The AI-driven drug discovery platforms market is witnessing rapid growth as biotech and pharma companies adopt AI to streamline discovery pipelines. These platforms cut costs and time-to-market for new drugs. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: AI-Driven Drug Discovery Platforms Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. AI-Driven Drug Discovery Platforms Market, by Functional Workflow/Application
8.1.1. Target identification and validation
8.1.1.1. Market Revenue and Forecast
8.1.2. Hit discovery (virtual screening/docking/generative chemistry)
8.1.2.1. Market Revenue and Forecast
8.1.3. Lead optimization and multi-parameter optimization
8.1.3.1. Market Revenue and Forecast
8.1.4. ADMET/toxicity prediction and in-silico safety profiling
8.1.4.1. Market Revenue and Forecast
8.1.5. Drug repurposing and indication discovery
8.1.5.1. Market Revenue and Forecast
8.1.6. Biomarker discovery and translational modeling
8.1.6.1. Market Revenue and Forecast
8.1.7. Clinical trial design and patient stratification
8.1.7.1. Market Revenue and Forecast
9.1. AI-Driven Drug Discovery Platforms Market, by Modality Supported
9.1.1. Small molecules
9.1.1.1. Market Revenue and Forecast
9.1.2. Biologics (antibodies, proteins)
9.1.2.1. Market Revenue and Forecast
9.1.3. Peptides and macrocycles
9.1.3.1. Market Revenue and Forecast
9.1.4. RNA modalities (siRNA, ASO, mRNA)
9.1.4.1. Market Revenue and Forecast
9.1.5. Cell and gene therapy enabling analytics
9.1.5.1. Market Revenue and Forecast
10.1. AI-Driven Drug Discovery Platforms Market, by Core AI/Technology Stack
10.1.1. Deep learning (CNNs, RNNs) and graph neural networks (GNNs)
10.1.1.1. Market Revenue and Forecast
10.1.2. Generative models (VAEs, GANs, diffusion models)
10.1.2.1. Market Revenue and Forecast
10.1.3. NLP/knowledge graph and literature mining
10.1.3.1. Market Revenue and Forecast
10.1.4. Physics-informed ML/hybrid QM-ML approaches
10.1.4.1. Market Revenue and Forecast
10.1.5. Reinforcement learning for molecular design
10.1.5.1. Market Revenue and Forecast
11.1. AI-Driven Drug Discovery Platforms Market, by Therapeutic Area Focus
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. CNS/neurological disorders
11.1.2.1. Market Revenue and Forecast
11.1.3. Rare diseases and orphan indications
11.1.3.1. Market Revenue and Forecast
11.1.4. Cardiometabolic diseases
11.1.4.1. Market Revenue and Forecast
11.1.5. Infectious diseases and antivirals
11.1.5.1. Market Revenue and Forecast
11.1.6. Immunology/inflammation
11.1.6.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Functional Workflow/Application
12.1.2. Market Revenue and Forecast, by Modality Supported
12.1.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.1.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.1.5.2. Market Revenue and Forecast, by Modality Supported
12.1.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Functional Workflow/Application
12.1.6.2. Market Revenue and Forecast, by Modality Supported
12.1.6.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.2. Europe
12.2.1. Market Revenue and Forecast, by Functional Workflow/Application
12.2.2. Market Revenue and Forecast, by Modality Supported
12.2.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.2.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.2.5.2. Market Revenue and Forecast, by Modality Supported
12.2.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Functional Workflow/Application
12.2.6.2. Market Revenue and Forecast, by Modality Supported
12.2.6.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Functional Workflow/Application
12.2.7.2. Market Revenue and Forecast, by Modality Supported
12.2.7.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Functional Workflow/Application
12.2.8.2. Market Revenue and Forecast, by Modality Supported
12.2.8.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.3. APAC
12.3.1. Market Revenue and Forecast, by Functional Workflow/Application
12.3.2. Market Revenue and Forecast, by Modality Supported
12.3.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.3.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.3.5.2. Market Revenue and Forecast, by Modality Supported
12.3.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Functional Workflow/Application
12.3.6.2. Market Revenue and Forecast, by Modality Supported
12.3.6.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Functional Workflow/Application
12.3.7.2. Market Revenue and Forecast, by Modality Supported
12.3.7.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Functional Workflow/Application
12.3.8.2. Market Revenue and Forecast, by Modality Supported
12.3.8.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.4. MEA
12.4.1. Market Revenue and Forecast, by Functional Workflow/Application
12.4.2. Market Revenue and Forecast, by Modality Supported
12.4.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.4.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.4.5.2. Market Revenue and Forecast, by Modality Supported
12.4.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Functional Workflow/Application
12.4.6.2. Market Revenue and Forecast, by Modality Supported
12.4.6.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Functional Workflow/Application
12.4.7.2. Market Revenue and Forecast, by Modality Supported
12.4.7.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Functional Workflow/Application
12.4.8.2. Market Revenue and Forecast, by Modality Supported
12.4.8.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.5.2. Market Revenue and Forecast, by Modality Supported
12.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Functional Workflow/Application
12.5.5.2. Market Revenue and Forecast, by Modality Supported
12.5.5.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Focus
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Functional Workflow/Application
12.5.6.2. Market Revenue and Forecast, by Modality Supported
12.5.6.3. Market Revenue and Forecast, by Core AI/Technology Stack
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Focus
13.1. Atomwise
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. BenevolentAI
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Cloud Pharmaceuticals
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. DeepMind (Alphabet)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Exscientia
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Healx
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Insilico Medicine
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. LabGenius
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Numerate
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description